P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

MLA

Juan Turnes, et al. “P- 24 Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-Acting Antivirals for the Treatment of Hepatitis C.” Annals of Hepatology, vol. 28, no. 100926-, Mar. 2023. EBSCOhost, https://doi.org/10.1016/j.aohep.2023.100926.

APA

Juan Turnes, Antonio García-Herola, Ramón Morillo, Marinela Méndez, Magdalena Rueda, Cándido Hernández, Antoni Sicras-Mainar, & Jorge Mendez-Navarro. (2023). P- 24 Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-Acting Antivirals for the Treatment of Hepatitis C. Annals of Hepatology, 28(100926-). https://doi.org/10.1016/j.aohep.2023.100926

Chicago

Juan Turnes, Antonio García-Herola, Ramón Morillo, Marinela Méndez, Magdalena Rueda, Cándido Hernández, Antoni Sicras-Mainar, and Jorge Mendez-Navarro. 2023. “P- 24 Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-Acting Antivirals for the Treatment of Hepatitis C.” Annals of Hepatology 28 (100926-). doi:10.1016/j.aohep.2023.100926.